SK2882003A3 - Receptor in the EDb fibronectin domain - Google Patents

Receptor in the EDb fibronectin domain Download PDF

Info

Publication number
SK2882003A3
SK2882003A3 SK288-2003A SK2882003A SK2882003A3 SK 2882003 A3 SK2882003 A3 SK 2882003A3 SK 2882003 A SK2882003 A SK 2882003A SK 2882003 A3 SK2882003 A3 SK 2882003A3
Authority
SK
Slovakia
Prior art keywords
protein
fibronectin
domain
cells
seq
Prior art date
Application number
SK288-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Alexander REDLITZ
Marcus Koppitz
Ursula Egner
Inke Bahr
Andreas Menrad
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10045803A external-priority patent/DE10045803A1/de
Priority claimed from DE2001123133 external-priority patent/DE10123133A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of SK2882003A3 publication Critical patent/SK2882003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
SK288-2003A 2000-09-07 2001-08-30 Receptor in the EDb fibronectin domain SK2882003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045803A DE10045803A1 (de) 2000-09-07 2000-09-07 Rezeptor der EDb Fibronektin-Domäne
DE2001123133 DE10123133A1 (de) 2001-05-02 2001-05-02 Rezeptor der ED¶b¶-Fibronektin-Domäne (II)
PCT/EP2001/010016 WO2002020563A2 (fr) 2000-09-07 2001-08-30 RECEPTEUR DU DOMAINE DE LA EDb-FIBRONECTINE

Publications (1)

Publication Number Publication Date
SK2882003A3 true SK2882003A3 (en) 2003-08-05

Family

ID=26007070

Family Applications (1)

Application Number Title Priority Date Filing Date
SK288-2003A SK2882003A3 (en) 2000-09-07 2001-08-30 Receptor in the EDb fibronectin domain

Country Status (23)

Country Link
US (3) US20020197700A1 (fr)
EP (1) EP1381629B1 (fr)
JP (1) JP2004529848A (fr)
KR (1) KR20030045056A (fr)
CN (1) CN1246333C (fr)
AT (1) ATE407951T1 (fr)
AU (1) AU1218202A (fr)
BG (1) BG107614A (fr)
BR (1) BR0113737A (fr)
CA (1) CA2421783A1 (fr)
DE (1) DE50114321D1 (fr)
EE (1) EE200300092A (fr)
ES (1) ES2312478T3 (fr)
HR (1) HRP20030263A2 (fr)
HU (1) HUP0300935A3 (fr)
IL (1) IL154778A0 (fr)
NO (1) NO20031033L (fr)
NZ (1) NZ524342A (fr)
PL (1) PL364358A1 (fr)
RU (1) RU2280254C2 (fr)
SK (1) SK2882003A3 (fr)
WO (1) WO2002020563A2 (fr)
YU (1) YU17503A (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE463512T1 (de) 2005-11-09 2010-04-15 Morphosys Ag Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1892248A1 (fr) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Protéines liantes spécifiques et de haute affinité comprenant des domaines SH3 de FYN kinase modifiés
WO2008120101A2 (fr) 2007-04-02 2008-10-09 Philogen S.P.A. Nouvel antigène associé à la néovasculature de métastases tumorales
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
DK3281952T3 (da) 2007-10-30 2020-08-03 Philogen Spa Antigen, der er forbundet med reumatoid artritis
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2461832B1 (fr) 2009-08-05 2017-06-28 Philogen S.p.A. Ciblage de la néovascularisation de la moelle osseuse
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
CN111148759B (zh) * 2017-09-30 2023-09-19 合肥立方制药股份有限公司 结合至纤维连接蛋白b结构域的蛋白
EP4384203A4 (fr) * 2021-08-09 2025-09-03 Rajan Gunesh Compositions et procédés de cicatrisation de plaies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
EP0330506A3 (fr) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Protéines VLA
US5177015A (en) * 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
DK0486622T3 (da) * 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5120830A (en) * 1990-10-25 1992-06-09 Washington University Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
CA2372813A1 (fr) * 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
US5561114A (en) * 1992-09-25 1996-10-01 Otsuka Pharmaceutical Factory Inc. Adsorbent for cellular fibronectin, a method for fractional purification of fibronectin and a method of hemocatharisis
JP3339724B2 (ja) * 1992-09-29 2002-10-28 株式会社リコー インクジェット記録方法及びその装置
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) * 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
WO1997002479A2 (fr) * 1995-06-30 1997-01-23 Yale University Anticorps anti-tumoraux monoclonaux humains
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5842156A (en) * 1996-11-12 1998-11-24 The United States Of America As Represented By The Secretary Of The Air Force Multirate multiresolution target tracking
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) * 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) * 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US5997842A (en) * 1998-04-13 1999-12-07 Light Sciences Limited Partnership Radionuclide excited phosphorescent material for administering PDT
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
AU2001239470A1 (en) * 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
AR040956A1 (es) * 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico

Also Published As

Publication number Publication date
WO2002020563A2 (fr) 2002-03-14
JP2004529848A (ja) 2004-09-30
PL364358A1 (en) 2004-12-13
RU2003109431A (ru) 2005-01-20
ATE407951T1 (de) 2008-09-15
HUP0300935A2 (hu) 2003-12-29
CN1246333C (zh) 2006-03-22
KR20030045056A (ko) 2003-06-09
US20020197700A1 (en) 2002-12-26
HRP20030263A2 (en) 2005-10-31
WO2002020563A3 (fr) 2003-10-09
NO20031033D0 (no) 2003-03-06
IL154778A0 (en) 2003-10-31
DE50114321D1 (de) 2008-10-23
HK1064683A1 (en) 2005-02-04
EP1381629B1 (fr) 2008-09-10
NO20031033L (no) 2003-05-07
BR0113737A (pt) 2004-02-25
US20050221434A1 (en) 2005-10-06
YU17503A (sh) 2006-05-25
HUP0300935A3 (en) 2005-09-28
NZ524342A (en) 2005-09-30
EE200300092A (et) 2005-06-15
CN1487953A (zh) 2004-04-07
ES2312478T3 (es) 2009-03-01
CA2421783A1 (fr) 2002-03-14
BG107614A (bg) 2003-12-31
US20050089941A1 (en) 2005-04-28
AU1218202A (en) 2002-03-22
EP1381629A2 (fr) 2004-01-21
RU2280254C2 (ru) 2006-07-20

Similar Documents

Publication Publication Date Title
Penta et al. Del1 induces integrin signaling and angiogenesis by ligation of αVβ3
US5641869A (en) Method for purifying heregulin
US5367060A (en) Structure, production and use of heregulin
US5859206A (en) Antibodies specific for heregulin 2-α
US5607918A (en) Vascular endothelial growth factor-B and DNA coding therefor
Roach et al. Preparation of a monoclonal antibody specific for the class I isotype of β‐tubulin: The β isotypes of tubulin differ in their cellular distributions within human tissues
Brösicke et al. Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels
JPH09507750A (ja) Ｗｎｔ−ｘ増殖因子をコードするＤＮＡ
SK2882003A3 (en) Receptor in the EDb fibronectin domain
JP2002517182A (ja) インテグリンヘテロ二量体およびそのサブユニット
WO2001049743A9 (fr) Procedes de modulation du systeme immunitaire
WO2005040191A2 (fr) Compositions de ccn1 et methodes associees
ZA200302629B (en) Receptor in the EDb fibronectin domain.
US20060240002A1 (en) Methods of inhibiting angiogenesis-dependent conditions mediated by cryptic epitopes of extracellular matrix components
US20060216236A1 (en) Methods of inhibiting alphavBeta3-mediated angiogenesis and tumor development
WO1998037195A9 (fr) Proteines morphogeniques
Kemp Focal adhesion kinase signalling in endothelial cells
McFall Molecular interactions of the extracellular protein domain of syndecan-4
Stoletov Role of Nck and Crk adapter proteins in the VEGF promoted endothelial cell migration
WO2006098987A2 (fr) Methodes d'inhibition de l'angiogenese et du developpement tumoral

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure